What Is Tirzepatide? Mechanism, Research, and How It Compares

Tirzepatide is a synthetic peptide that acts as a dual agonist for two hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Developed by Eli Lilly, it is the active compound in Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management). It represents the second generation of the GLP-1 class, following semaglutide, and preceded retatrutide in the research pipeline.

How Tirzepatide Works

The GLP-1 receptor pathway reduces appetite by slowing gastric emptying and acting on satiety centers in the brain. This mechanism is shared with semaglutide. The addition of GIP receptor agonism is what distinguishes tirzepatide. GIP is an incretin hormone that enhances insulin secretion in response to food and appears to play a role in fat storage and release. Research suggests that GIP receptor activation may increase the effectiveness of GLP-1 agonism, rather than simply adding a parallel effect.

The interaction between GLP-1 and GIP pathways in metabolic regulation is still being studied. One hypothesis is that GIP receptor activation helps redistribute fat storage in a way that supports the energy deficit created by GLP-1 activation. Another is that the combined receptor occupancy produces greater satiety than either alone. The exact mechanism of the enhanced efficacy is an active research question.

SURMOUNT Trial Results

The SURMOUNT clinical trial program established the efficacy data for tirzepatide in weight management. SURMOUNT-1 enrolled adults with obesity without diabetes and showed average weight loss of approximately 20.9% over 72 weeks at the highest dose (15mg weekly). SURMOUNT-2 studied adults with obesity and type 2 diabetes, showing average weight loss of approximately 15.7% over 72 weeks.

These figures are substantially higher than those seen in comparable semaglutide trials (STEP trials), where average weight loss was approximately 15% over 68 weeks. The additional efficacy is attributed to the dual receptor mechanism, though trial populations and protocols differ, making direct comparison imperfect.

How Tirzepatide Compares to Semaglutide and Retatrutide

Tirzepatide outperforms semaglutide in trial efficacy data, which has been the basis for significant research and clinical interest. Retatrutide, which adds glucagon receptor agonism on top of the GLP-1 and GIP mechanisms in tirzepatide, showed even higher efficacy in Phase 2 trials (approximately 24% weight loss over 48 weeks). Tirzepatide sits between semaglutide and retatrutide in the current efficacy hierarchy, with the most accumulated clinical data of the three after semaglutide.

Side Effects Documented in Trials

Tirzepatide's side effect profile is consistent with the broader GLP-1 class. Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) are the most common, dose-dependent, and most pronounced during dose escalation. Gallbladder events, including cholelithiasis, are documented. Injection site reactions occur at a low rate. The thyroid C-cell tumor signal seen in rodent studies for semaglutide has also been observed for tirzepatide, carrying the same black box warning, without human confirmation.

Tirzepatide in Cardiovascular Research

The SURPASS-CVOT trial (SURMOUNT-MMO) is investigating cardiovascular outcomes in people with obesity and established cardiovascular disease, similar to the SELECT trial design for semaglutide. Results from this trial will be important for understanding whether tirzepatide's additional receptor mechanism translates to cardiovascular benefit beyond semaglutide.

Werner Science carries research-grade tirzepatide and other GLP-1 compounds. Browse their catalog at wernerscience.com/?ref=bwmucbwp and use code SAVE10 for a discount.